MarketCap
Facebook
X
TelegramQuarterly report 2024-Q3
added 10-29-2024
10x Genomics Revenue 2011-2025 | TXG
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue 10x Genomics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 619 M | 516 M | 490 M | 299 M | 246 M | 146 M | 71.1 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 619 M | 71.1 M | 341 M |
Quarterly Revenue 10x Genomics
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 152 M | 153 M | 141 M | 154 M | 147 M | 134 M | - | - | 115 M | 114 M | - | 125 M | 116 M | 106 M | - | 71.8 M | 42.9 M | 71.9 M | 75.3 M | 61.2 M | 55.8 M | 53.6 M | 50.6 M | 36.6 M | 31.7 M | 27.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 154 M | 27.4 M | 92.5 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Health information services industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Cerner Corporation
CERN
|
5.76 B | - | - | $ 27.9 B |  USA |
 |
Computer Programs and Systems
CPSI
|
339 M | - | 4.4 % | $ 133 M | USA |
 |
Covetrus
CVET
|
4.58 B | - | - | $ 2.94 B | USA |
 |
Accolade
ACCD
|
170 M | - | 0.29 % | $ 206 M | USA |
 |
Castlight Health, Inc.
CSLT
|
147 M | - | -7.28 % | $ 227 M | USA |
 |
HMS Holdings Corp.
HMSY
|
673 M | - | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
668 M | - | - | $ 6.37 B | USA |
 |
Change Healthcare
CHNG
|
3.09 B | - | - | $ 9.03 B | USA |
 |
Evolent Health
EVH
|
382 M | $ 4.11 | -0.48 % | $ 385 M | USA |
 |
Health Catalyst
HCAT
|
307 M | $ 2.34 | -4.82 % | $ 141 M | USA |
 |
HealthStream
HSTM
|
292 M | $ 24.4 | 0.95 % | $ 741 M | USA |
 |
iCAD
ICAD
|
19.6 M | - | - | $ 102 M | USA |
 |
Akerna Corp.
KERN
|
20.5 M | - | - | $ 161 M | USA |
 |
HealthEquity
HQY
|
262 M | $ 96.06 | -0.75 % | $ 8.22 B | USA |
 |
OptimizeRx Corporation
OPRX
|
71.5 M | $ 13.18 | -1.35 % | $ 226 M | USA |
 |
American Well Corporation
AMWL
|
254 M | $ 4.68 | 1.3 % | $ 70.2 M | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
1.5 B | - | -10.39 % | $ 886 M | USA |
 |
Progyny
PGNY
|
298 M | $ 26.39 | -1.2 % | $ 2.26 B | USA |
 |
Premier
PINC
|
263 M | $ 28.26 | - | $ 2.33 B | USA |
 |
MTBC
MTBC
|
111 M | - | -0.58 % | $ 51.7 M | USA |
 |
GoodRx Holdings
GDRX
|
792 M | $ 2.72 | -3.72 % | $ 1.05 B | USA |
 |
Schrödinger
SDGR
|
208 M | $ 18.41 | 1.99 % | $ 1.34 B | USA |
 |
Omnicell
OMCL
|
1.11 B | $ 43.31 | -1.25 % | $ 1.99 B | USA |
 |
1Life Healthcare
ONEM
|
623 M | - | - | $ 3.37 B | USA |
 |
Phreesia
PHR
|
356 M | $ 16.68 | 2.71 % | $ 910 M | USA |
 |
So-Young International
SY
|
-1.52 M | $ 2.92 | -5.66 % | $ 232 M |  China |
 |
Signify Health
SGFY
|
184 M | - | -0.02 % | $ 7.21 B | USA |
 |
R1 RCM
RCM
|
1.47 B | - | - | $ 3.81 B | USA |
 |
NantHealth
NH
|
67 M | - | -46.64 % | $ 10.4 M | USA |
 |
NextGen Healthcare
NXGN
|
557 M | - | - | $ 1.6 B | USA |
 |
Veeva Systems
VEEV
|
2.36 B | $ 219.17 | -1.81 % | $ 35.2 B | USA |
 |
Zhongchao
ZCMD
|
16.3 M | $ 0.58 | -3.18 % | $ 3.02 M | China |
 |
Streamline Health Solutions
STRM
|
17.9 M | - | - | $ 21.4 M | USA |
 |
Teladoc Health
TDOC
|
2.57 B | $ 7.36 | -2.65 % | $ 1.26 B | USA |
 |
Tabula Rasa HealthCare
TRHC
|
300 M | - | - | $ 255 M | USA |
 |
SCWorx Corp.
WORX
|
2.99 M | $ 0.21 | 5.86 % | $ 306 K | USA |